Kiniksa Pharmaceuticals International (KNSA) EBITDA Margin (2021 - 2026)
Kiniksa Pharmaceuticals International (KNSA) reported EBITDA Margin of 10.25% for Q1 2026, up 405.0% on a YoY basis from 2.03% in Q1 2025, and up 44.52% quarter-over-quarter from 7.09% in Q4 2025.
Kiniksa Pharmaceuticals International (KNSA) EBITDA Margin (2021 - 2026) Analysis & Trends
Kiniksa Pharmaceuticals International has reported EBITDA Margin for 6 years, with the latest figure at 10.25% in Q1 2026.
- For the quarter ending Q1 2026, EBITDA Margin rose 405.0% year-over-year to 10.25%; the trailing twelve-month figure through Mar 2026 stood at 9.62% (up 1317.0% YoY), and the FY2025 full-year result was 8.73%, up 1897.0% from the prior year.
- EBITDA Margin for Q1 2026 stood at 10.25%, up from 7.09% in the prior quarter.
- The five-year high for EBITDA Margin was 226.07% in Q3 2022, with the low at 78.43% in Q1 2022.
- Historically, EBITDA Margin has averaged 4.49% across 5 years, with a median of 3.09% in 2022.
- Annual changes were most pronounced in 2022 — EBITDA Margin surged 47920 bps — and 2023, when it tumbled 24675 bps.
- Kiniksa Pharmaceuticals International's EBITDA Margin stood at 3.09% in 2022, then soared by 1081 bps to 30.27% in 2023, then sank by 124 bps to 7.35% in 2024, then surged by 196 bps to 7.09% in 2025, then surged by 45 bps to 10.25% in 2026.
- The last three EBITDA Margin figures came in at 10.25% (Q1 2026), 7.09% (Q4 2025), and 10.14% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | 16.37% |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | 36.83% |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | 41.69% |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | -1.01% |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | 22.74% |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | 22.39% |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | -170.35% |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | 21.55% |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | -16.25% |
| 10 | Kiniksa Pharmaceuticals International | 3.76 Bn | 3.29 Bn | 193.47 Mn | 10.25% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.25% |
| Dec 31, 2025 | 7.09% |
| Sep 30, 2025 | 10.14% |
| Jun 30, 2025 | 11.44% |
| Mar 31, 2025 | 6.20% |
| Dec 31, 2024 | -7.35% |
| Sep 30, 2024 | -11.23% |
| Jun 30, 2024 | -3.67% |
| Mar 31, 2024 | -22.24% |
| Dec 31, 2023 | 30.27% |
| Sep 30, 2023 | -20.69% |
| Jun 30, 2023 | 20.89% |
| Mar 31, 2023 | -25.36% |
| Dec 31, 2022 | -3.09% |
| Sep 30, 2022 | 226.07% |
| Jun 30, 2022 | -74.03% |
| Mar 31, 2022 | -78.43% |
| Dec 31, 2021 | -193.94% |
| Sep 30, 2021 | -253.13% |
| Jun 30, 2021 | -538.88% |